PET scans to optimize tuberculosis meningitis treatments and personalize care, study finds

December 6, 2018, Johns Hopkins University School of Medicine
Gram stain of meningococci from a culture showing Gram negative (pink) bacteria, often in pairs. Credit: public domain

Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain—or tuberculosis meningitis (TBM)—is often deadly, always hard to treat, and a particular threat to young children. It may leave survivors with lifelong brain damage. Now, researchers at Johns Hopkins Medicine report they have used PET scans, a rabbit model and a specially tagged version of the TB drug rifampin to advance physicians' understanding of this disease by showing precisely how little rifampin ever reaches the sites of TB infection in the brain.

"Really precise information has never been easy to come by for how much rifampin gets to any given patient where it's needed," says corresponding author Sanjay Jain, M.D., professor of pediatrics, radiology and international health at the Johns Hopkins University School of Medicine. "We've been able to use technology to find that long-needed information about this very troubling disease."

Jain, along with lead authors Elizabeth Tucker, M.D., assistant professor of anesthesiology and critical care medicine, and Alvaro Ordonez, M.D., research associate, pediatric infectious diseases at the Johns Hopkins University School of Medicine, as well as other Johns Hopkins and University of Maryland colleagues, published their findings Dec. 5 in Science Translational Medicine.

Tuberculosis, which mostly infects the lungs, sickens more than 10 million people around the world each year, causes more than 1 million deaths and costs the global economy billions of dollars, according to the World Health Organization. TBM, caused when Mycobacterium tuberculosis infects brain tissue and the fluid surrounding the brain and spinal cord, is considered the most lethal and disabling form of TB. Children under the age of 5, and those with chronic diseases—notably diabetes and HIV—are mostly likely to develop TBM. Like all TB diseases, TBM is treated with a combination of drugs, including isoniazid, rifampin and pyrazinamide, taken for a year. However, even with treatment, over half of patients die or have significant neurological injury lasting a lifetime, especially .

In the new study, Johns Hopkins researchers engineered a version of rifampin with a charged particle—called a positron—attached to the ([11C]rifampin) that allowed them to follow its movement throughout the body using PET (positron emission tomography) scans.

Because TBM symptoms are similar among rabbits and humans, the researchers created an experimentally infected colony of rabbits with TBM, injected them with the tagged drug and tracked levels of the tagged [11C]rifampin throughout the rabbits' brains over six weeks. PET scans revealed that after two weeks of treatment, the penetration of [11C]rifampin into TBM brain lesions significantly decreased, from 32 percent to only 11 percent of the levels of the drug noted in the blood. Significantly, they say, the decrease was not reflected in samples of cerebrospinal fluid (CSF) taken from the rabbits, despite that CSF is currently used as a standard proxy for determining drug and infection levels in people.

"Until now, when treating patients, we've relied on a needle biopsy," says Tucker. "We've assumed that what's happening at the tip of the needle at one time point in a sample is what's happening throughout the affected organ." The new results in the rabbit model, she says, suggest that it's not that simple, at least in the animals. The penetration of rifampin varied among TBM lesions even within a single animal, and changed over the course of the long treatment timeline.

The researchers also gave the tagged version of the drug to 10 adult human TB patients already receiving rifampin therapy. The patients were scanned at the Johns Hopkins PET Center in Baltimore, and these studies were performed under Food and Drug Administration guidelines for new PET tracers. One of the patients, a 24-year-old female, had TBM. Similar to the results in rabbits, a PET scan showed that penetration of the drug into the patient's brain lesions was limited to less than 5 percent.

The findings, the researchers say, help advance understanding of why current drug treatments for TBM may not be as effective. And they say the PET approach offers a potential way to optimize the treatment of TBM, to ensure that enough drug is reaching the infected lesions.

"If further research in animals and humans confirms that and other anti-TB drugs penetrate differently into their brains," says Ordonez, "we foresee that imaging can help us figure out the concentration of drug needed and tailor the dose for individual patients."

The team also expects that the rabbit model of TBM can be used to answer key questions about the disease and its treatment, including what baseline levels of antibiotics are required to penetrate lesions more fully.

"We used to think we could just give a drug and patients should get better," says Jain. "Now, we have tools to measure the nuances that make a difference. PET could be used to study other antibiotics and also allow precision medicine approaches in resource-rich settings, such as the U.S. for other serious infections including MRSA (methicillin-resistant Staphylococcus aureus)."

Explore further: Higher doses of rifampin appear more effective in fighting tuberculosis without increasing risk of adverse events

More information: Elizabeth W. Tucker et al, Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis, Science Translational Medicine (2018). DOI: 10.1126/scitranslmed.aau0965

Related Stories

Higher doses of rifampin appear more effective in fighting tuberculosis without increasing risk of adverse events

June 29, 2018
Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, killed more TB bacteria in sputum cultures, and the higher doses did so without increasing the adverse effects of treatment, according to a randomized ...

MICs of isoniazid, rifampin may predict tuberculosis relapse

August 30, 2018
(HealthDay)—In pretreatment isolates of Mycobacterium tuberculosis, higher minimum inhibitory concentrations (MICs) of isoniazid and rifampin below the standard resistance breakpoint are associated with increased risk of ...

Latent TB treatment: Shorter is better

August 1, 2018
Treatment of latent tuberculosis is set to transform after a pair of studies from the Research-Institute of the McGill University Health Centre (RI-MUHC) revealed that a shorter treatment was safer and more effective in children ...

Adding blood pressure drug to standard antibiotics speeds up TB treatment

August 29, 2013
Infectious disease experts at Johns Hopkins have found, in studies in mice, that a drug better known as a treatment for high blood pressure and headaches effectively speeds up treatment of TB when added to the standard, daily ...

Mouse studies show experimental TB treatment may do more harm than good

September 6, 2016
Johns Hopkins researchers report evidence from mouse studies that a "repurposed" drug that would be expected to improve the immune system response of tuberculosis patients may be increasing resistance to the antibiotic drugs ...

Recommended for you

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Human antibody discovery could save lives from fungal killer

December 11, 2018
A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism

December 11, 2018
Treatment with active vitamin D did not decrease cardiovascular events in kidney patients undergoing hemodialysis, according to a research group in Japan. They have reported their research results in the December 11 issue ...

Dialysis patients at risk of progressive brain injury

December 10, 2018
Kidney dialysis can cause short-term 'cerebral stunning' and may be associated with progressive brain injury in those who receive the treatment for many years. For many patients with kidney failure awaiting a kidney transplant ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

PET scans to optimize tuberculosis meningitis treatments and personalize care, study finds

December 6, 2018
Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain—or tuberculosis meningitis (TBM)—is often deadly, always hard to treat, and a particular ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.